Logo image of EDSA

EDESA BIOTECH INC (EDSA) Stock Fundamental Analysis

NASDAQ:EDSA - Nasdaq - CA27966L3065 - Common Stock - Currency: USD

2.5  -0.19 (-7.06%)

After market: 2.47 -0.03 (-1.2%)

Fundamental Rating

1

Overall EDSA gets a fundamental rating of 1 out of 10. We evaluated EDSA against 571 industry peers in the Biotechnology industry. The financial health of EDSA is average, but there are quite some concerns on its profitability. EDSA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EDSA had negative earnings in the past year.
In the past year EDSA has reported a negative cash flow from operations.
EDSA had negative earnings in each of the past 5 years.
In the past 5 years EDSA always reported negative operating cash flow.
EDSA Yearly Net Income VS EBIT VS OCF VS FCFEDSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

EDSA's Return On Assets of -161.77% is on the low side compared to the rest of the industry. EDSA is outperformed by 86.86% of its industry peers.
EDSA has a Return On Equity of -311.44%. This is in the lower half of the industry: EDSA underperforms 76.38% of its industry peers.
Industry RankSector Rank
ROA -161.77%
ROE -311.44%
ROIC N/A
ROA(3y)-112.41%
ROA(5y)-88.99%
ROE(3y)-135.95%
ROE(5y)-106.1%
ROIC(3y)N/A
ROIC(5y)N/A
EDSA Yearly ROA, ROE, ROICEDSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

EDSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EDSA Yearly Profit, Operating, Gross MarginsEDSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

EDSA has more shares outstanding than it did 1 year ago.
EDSA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for EDSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EDSA Yearly Shares OutstandingEDSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
EDSA Yearly Total Debt VS Total AssetsEDSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

EDSA has an Altman-Z score of -24.57. This is a bad value and indicates that EDSA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -24.57, EDSA is not doing good in the industry: 89.34% of the companies in the same industry are doing better.
There is no outstanding debt for EDSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.57
ROIC/WACCN/A
WACCN/A
EDSA Yearly LT Debt VS Equity VS FCFEDSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

EDSA has a Current Ratio of 0.91. This is a bad value and indicates that EDSA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.91, EDSA is not doing good in the industry: 89.34% of the companies in the same industry are doing better.
A Quick Ratio of 0.91 indicates that EDSA may have some problems paying its short term obligations.
With a Quick ratio value of 0.91, EDSA is not doing good in the industry: 88.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.91
Quick Ratio 0.91
EDSA Yearly Current Assets VS Current LiabilitesEDSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

EDSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.72%, which is quite impressive.
EPS 1Y (TTM)36.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.28% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.61%
EPS Next 2Y13.66%
EPS Next 3Y14.28%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EDSA Yearly Revenue VS EstimatesEDSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200K 400K 600K 800K 1M
EDSA Yearly EPS VS EstimatesEDSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EDSA. In the last year negative earnings were reported.
Also next year EDSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDSA Price Earnings VS Forward Price EarningsEDSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDSA Per share dataEDSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

EDSA's earnings are expected to grow with 14.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.66%
EPS Next 3Y14.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EDSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDESA BIOTECH INC

NASDAQ:EDSA (2/18/2025, 6:08:01 PM)

After market: 2.47 -0.03 (-1.2%)

2.5

-0.19 (-7.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17 2025-02-17
Earnings (Next)05-08 2025-05-08
Inst Owners11.87%
Inst Owner Change28.61%
Ins Owners23%
Ins Owner Change17.51%
Market Cap8.68M
Analysts82.86
Price Target20.91 (736.4%)
Short Float %0.72%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.73%
Min EPS beat(2)12.1%
Max EPS beat(2)47.35%
EPS beat(4)4
Avg EPS beat(4)33.42%
Min EPS beat(4)12.1%
Max EPS beat(4)56.25%
EPS beat(8)8
Avg EPS beat(8)32.37%
EPS beat(12)12
Avg EPS beat(12)33.37%
EPS beat(16)13
Avg EPS beat(16)13.42%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-20.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.38
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS0
BVpS0.57
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161.77%
ROE -311.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-112.41%
ROA(5y)-88.99%
ROE(3y)-135.95%
ROE(5y)-106.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.91
Quick Ratio 0.91
Altman-Z -24.57
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)5.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.67%
EPS Next Y-8.61%
EPS Next 2Y13.66%
EPS Next 3Y14.28%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.96%
OCF growth 3YN/A
OCF growth 5YN/A